SINOMED(688108)2025-01-24 10:15Revenue Projections - The company expects revenue for 2024 to be between 446.4 million and 461.3 million CNY, representing a year-on-year increase of 30% to 34%[3]. Profit Projections - The net profit attributable to shareholders is projected to range from -20 million to 3.7 million CNY, an increase of 1.963 million to 4.333 million CNY compared to the previous year, reflecting a growth of 50% to 109%[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -40 million and -15.3 million CNY, an increase of 971 thousand to 3.441 million CNY, indicating a growth of 20% to 69%[3]. Business Segment Growth - The coronary intervention business is anticipated to see a revenue increase of 59% year-on-year, driven by the implementation of the national volume-based procurement policy and increased sales of two stent products[5][6]. - The neuro-intervention business is expected to grow by 6% to 15%, primarily due to increased sales of intracranial stents despite a slight decrease in unit price[6]. Cost Management - Operating costs are projected to increase, but at a rate lower than revenue growth, due to economies of scale leading to a decrease in unit costs[7]. - Sales expenses are expected to rise, but the growth rate will be lower than that of revenue, reflecting increased marketing costs[8]. - Management expenses are anticipated to decrease slightly due to the production commencement of a subsidiary, leading to reduced operational costs[9]. - R&D expenses are expected to grow, but at a rate lower than revenue growth, due to increased project activity and milestone achievements[10]. - Asset impairment losses are projected to increase significantly due to low capacity utilization at a subsidiary, resulting in higher fixed cost allocation per product[11].